CRC Research Update — March 11, 2026
Today's colorectal cancer research highlights
The CRC Digest
Curated CRC research — accessible, accurate, actionable
Wednesday, March 11, 2026
IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
-
Circulating Tumor DNA Shows Promise for Predicting Stage III Recurrence Risk
A systematic review and meta-analysis found that detectable ctDNA after surgery in stage III colorectal cancer patients was associated with higher risk of cancer returning, potentially helping doctors identify who needs closer monitoring. (Clinical Colorectal Cancer)
-
Phase I Trial Tests New HER2-Targeted Drug in Advanced Colorectal Cancer
Trastuzumab rezetecan, a drug that delivers chemotherapy directly to HER2-expressing cancer cells, was tested in a multicenter Phase I trial for advanced gastric and colorectal cancers—early-stage safety and dosing study only. (Journal of Clinical Oncology)
-
Systematic Review Examines Immunotherapy Before Surgery for Rectal Cancer
Researchers reviewed studies on neoadjuvant immunotherapy (treatment before surgery) in localized rectal cancer, analyzing its impact on tumor response and surgical outcomes. (Clinical Colorectal Cancer)
-
S-1 May Be Safe Alternative After Capecitabine Toxicity in Colon Cancer
A real-world study from the Netherlands found that switching to S-1 (an oral chemotherapy) after capecitabine-related side effects was feasible and safe for stage III colon cancer patients completing adjuvant treatment. (European Journal of Cancer)
Research continues to refine treatment approaches and monitoring strategies for colorectal cancer at all stages.
The CRC Digest
Research Intelligence for the Colorectal Cancer Community
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.